Core Viewpoint - The invention patent "Shortened Human Papillomavirus Type 16 L1 Protein" co-held by Xiamen Wantai Biological Pharmacy Enterprise Co., Ltd. and Xiamen University has won the China Patent Gold Award, marking a significant achievement in the field of intellectual property in China [1][3]. Group 1: Award Details - The awarded patent is recognized as the highest honor in China's intellectual property sector, following a previous win in 2012 for the "Monoclonal Antibody for Hepatitis E Virus" [3]. - The patent number for the awarded invention is ZL200810093816.8, and it is co-owned by Xiamen Wantai Biological Pharmacy Enterprise Co., Ltd. and Xiamen University [4]. Group 2: Vaccine Development - The patented technology has been utilized to produce China's first bivalent HPV vaccine (Xinkening) and the first nine-valent HPV vaccine (Xinkening 9) [5]. - This technology has successfully broken through the patent barriers and market monopolies of international vaccine giants, offering advantages such as simpler processes, high cost-effectiveness, high yield, and ease of scaling compared to foreign eukaryotic expression systems [5]. - A study published in July 2023 in The Lancet Infectious Diseases indicated that the domestically produced nine-valent HPV vaccine demonstrates protection comparable to imported counterparts [5].
国产HPV疫苗核心发明专利荣获中国专利金奖
Xin Hua Wang·2025-08-12 05:51